GL1X · GenesisL1 explorer

MolNFT v1 · #141813 · protein

Crystal structure of PAK4 in complex with inhibitor CZG353

5ZJW · SERINE/THREONINE-protein kinase pak 4: “Crystal structure of PAK4 in complex with inhibitor CZG353”. X-ray diffraction, 2 ligands (9EO, BCT), 2 pockets (best druggability 0.72). MolNFT v1 #141813 on GenesisL1: 3D structure, binding…

PDB
5ZJW
Type
protein
Length
293 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
SERINE/THREONINE-protein kinase pak 4
EC
2.7.11.1
UniProt
O96013
Ligands
9EO, BCT
Pockets
2 · best druggability 0.72

Structure

x-ray diffraction · 1 distinct chain · 40% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ASERINE/THREONINE-protein kinase pak 4 (EC 2.7.11.1)protein29340% helix, 18% strandO96013

Ligands and binding sites

  • 9EO · (3Z)-N-[(1S)-2-hydroxy-1-phenylethyl]-3-[(1H-imidazol-2-yl)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-5-carboxamide · ligand · chains A
  • BCT · Bicarbonate ion · ligand · chains A
  • EDO · 1,2-ethanediol · additive · 8 copies · chains A
  • TRS · 2-amino-2-hydroxymethyl-propane-1,3-diol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13820.720.83509EO, EDO
2610.350.7815empty

Modifications

Observed in the structure: 1 modified (phosphorylation).

Compared structures

  • 5ZJW · Crystal Structure of PAK4 in complex with inhibitor CZg353 · the same entry in another collection · chain A against A, TM-score 1.00
  • O96013 · AlphaFold monomer V2.0 prediction for SERINE/THREONINE-protein kinase pak 4 (O96013) · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.